{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T14:10:13Z","timestamp":1742739013202,"version":"3.40.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-025-00615-x","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T13:34:41Z","timestamp":1742736881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa"],"prefix":"10.1186","volume":"23","author":[{"given":"Mark T.","family":"Verryn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"issue":"10152","key":"615_CR1","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0140-6736(18)31992-5","volume":"392","author":"United Nations","year":"2018","unstructured":"United Nations. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet. 2018;392(10152):1072\u201388.","journal-title":"Lancet"},{"key":"615_CR2","volume-title":"Global report on diabetes","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global report on diabetes. Geneva: World Health Organization; 2016."},{"issue":"10258","key":"615_CR3","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"Global Burden of Disease Study","year":"2020","unstructured":"Global Burden of Disease Study. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322.","journal-title":"Lancet"},{"issue":"10","key":"615_CR4","doi-asserted-by":"crossref","first-page":"e1375","DOI":"10.1016\/S2214-109X(19)30374-2","volume":"7","author":"HN Gouda","year":"2019","unstructured":"Gouda HN, Charlson F, Sorsdahl K, Ahmadzada S, Ferrari AJ, Erskine H, et al. Burden of non-communicable diseases in sub-Saharan Africa, 1990 & 2013: results from the Global Burden of Disease Study. Lancet Glob Health. 2019;7(10):e1375\u201387.","journal-title":"Lancet Glob Health"},{"issue":"9693","key":"615_CR5","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0140-6736(09)61087-4","volume":"374","author":"BM Mayosi","year":"2009","unstructured":"Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D. The burden of non-communicable diseases in South Africa. Lancet. 2009;374(9693):934\u201347.","journal-title":"Lancet"},{"key":"615_CR6","unstructured":"International Diabetes Federation. Brussels. 2020. Available from: https:\/\/www.idf.org\/our-network\/regions-members\/africa\/members\/25-south-africa."},{"key":"615_CR7","unstructured":"Global Health Data Exchange. Prevalence of Type 1 Diabetes in South Africa 2019 Available from: http:\/\/ghdx.healthdata.org\/gbd-results-tool."},{"issue":"12","key":"615_CR8","volume":"2020","author":"E Ipsen","year":"2020","unstructured":"Ipsen E, Hemmingsen B, Petersen L, Metzendorf M-I, Richter B. Definitions and reporting of hypoglycaemia in trials of long-acting insulin analogues in people with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2020;2020(12): CD013824.","journal-title":"Cochrane Database Syst Rev"},{"key":"615_CR9","unstructured":"South African Health Products Regulatory Authority. Registered Health Products."},{"key":"615_CR10","unstructured":"South African National Department of Health. Standard Treatment Guidelines and Essential Medicines List for South Africa. Hospital Level, Adults. PHC Chapter 9: Endocrine Conditions. 7 ed. South Africa: National Department of Health 2020."},{"key":"615_CR11","unstructured":"All Wales Therapeutics and Toxicology Centre. AWMSG Secretariat Assessment Report. Insulin degludec (Tresiba\u00ae) 100 units\/ml and 200 units\/ml solution for injection in prefilled pen (FlexTouch\u00ae) or 100 units\/ml solution for injection in cartridge (Penfill\u00ae). Reference number: 3158. 2016."},{"key":"615_CR12","unstructured":"All Wales Therapeutics and Toxicology Centre. AWMSG Secretariat Assessment Report. Insulin glargine (Abasaglar\u00ae) 100 units\/ml solution for injection. Reference number: 2307. 2015."},{"key":"615_CR13","volume-title":"Long-acting insulin analogues for diabetes mellitus: Meta-analysis of clinical outcomes and assessment of cost-effectiveness","author":"K Tran","year":"2007","unstructured":"Tran K, Banerjee S, Li H, Cimon K, Daneman D, Simpson S, et al. Long-acting insulin analogues for diabetes mellitus: Meta-analysis of clinical outcomes and assessment of cost-effectiveness. York (UK): Centre for Reviews and Dissemination; 2007."},{"key":"615_CR14","unstructured":"Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine [Internet]. NIHR Health Technology Assessment programme. 2007."},{"key":"615_CR15","unstructured":"National Institute for Health and Care Excellence (NICE). Type 1 diabetes in adults: diagnosis and management. Insulin therapy. Economic model report. United Kingdom; 2021."},{"issue":"1","key":"615_CR16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3111\/13696998.2014.971160","volume":"18","author":"M Evans","year":"2015","unstructured":"Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ. 2015;18(1):56\u201368.","journal-title":"J Med Econ"},{"issue":"3","key":"615_CR17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-5491.2011.03461.x","volume":"29","author":"WJ Valentine","year":"2012","unstructured":"Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabet Med. 2012;29(3):303\u201312.","journal-title":"Diabet Med"},{"issue":"2","key":"615_CR18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF02850126","volume":"23","author":"WJ Valentine","year":"2006","unstructured":"Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, et al. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther. 2006;23(2):191\u2013207.","journal-title":"Adv Ther"},{"issue":"4","key":"615_CR19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1185\/030079907X182194","volume":"23","author":"AJ Palmer","year":"2007","unstructured":"Palmer AJ, Valentine WJ, Ray JA, Foos V, Lurati F, Smith I, et al. An economic assessment of analogue basal\u2013bolus insulin versus human basal\u2013bolus insulin in subjects with type 1 diabetes in the UK. Curr Med Res Opin. 2007;23(4):895\u2013901.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"615_CR20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40258-018-0379-5","volume":"16","author":"WJ Valentine","year":"2018","unstructured":"Valentine WJ, Van Brunt K, Boye KS, Pollock RF. Treating type 1 diabetes mellitus with a rapid-acting analog insulin regimen vs. regular human insulin in Germany: a long-term cost-effectiveness evaluation. Appl Health Econ Health Policy. 2018;16(3):357\u201366.","journal-title":"Appl Health Econ Health Policy"},{"issue":"Suppl 2","key":"615_CR21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3111\/13696998.2012.713879","volume":"15","author":"M Pfohl","year":"2012","unstructured":"Pfohl M, Sch\u00e4dlich PK, Dippel FW, Koltermann KC. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany. J Med Econ. 2012;15(Suppl 2):14\u201327.","journal-title":"J Med Econ"},{"issue":"4","key":"615_CR22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1503\/cmaj.081180","volume":"180","author":"CG Cameron","year":"2009","unstructured":"Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. Can Med Assoc J. 2009;180(4):400.","journal-title":"Can Med Assoc J"},{"issue":"3","key":"615_CR23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00019053-200725030-00007","volume":"25","author":"DT Grima","year":"2007","unstructured":"Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics. 2007;25(3):253\u201366.","journal-title":"Pharmacoeconomics"},{"key":"615_CR24","unstructured":"Wilkinson T, Wilkinson M. Health Technology Assessment Methods Guide. To inform the selection of medicines to the South African National Essential Medicines List. South Africa. https:\/\/www.health.gov.za\/wp-content\/uploads\/2024\/04\/HTA-Methods-Guide_FINAL_Sep-2023.pdf.2021."},{"key":"615_CR25","unstructured":"X-Rates. Historical monthly average exchange rates. Available from: https:\/\/www.x-rates.com."},{"key":"615_CR26","unstructured":"TreeAge Software. TreeAge Pro, R1. Williamstown, MA; Available at http:\/\/www.treeage.com. 2021."},{"issue":"5","key":"615_CR27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/heapol\/czz152","volume":"35","author":"IP Edoka","year":"2020","unstructured":"Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Health Policy Plan. 2020;35(5):546\u201355.","journal-title":"Health Policy Plan"},{"key":"615_CR28","unstructured":"National Institute for Health and Care Excellence (NICE). Type 1 diabetes in adults: diagnosis and management: evidence reviews for long-acting insulins for optimal diabetic control. In: Service NH, editor. United Kingdom; 2021."},{"issue":"20","key":"615_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21200","volume":"21","author":"S Heller","year":"2017","unstructured":"Heller S, White D, Lee E, Lawton J, Pollard D, Waugh N, et al. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technol Assess. 2017;21(20):1\u2013278.","journal-title":"Health Technol Assess"},{"key":"615_CR30","unstructured":"U.S. Food and Drug Administration. Drug labelling information: LANTUS\u00ae (insulin glargine injection) for subcutaneous injection Initial U.S. Approval: 2000. 2018."},{"key":"615_CR31","unstructured":"U.S. Food and Drug Administration. Drug labelling information: LEVEMIR\u00ae (insulin detemir injection), for subcutaneous use Initial U.S. Approval: 2005. 2019."},{"key":"615_CR32","unstructured":"U.S. Food and Drug Administration. Drug labelling information: TOUJEO (insulin glargine injection) U-300, for subcutaneous use Initial U.S. Approval: 2015. 2015."},{"key":"615_CR33","unstructured":"U.S. Food and Drug Administration. Drug labelling information: TRESIBA\u00ae (insulin degludec injection), for subcutaneous use Initial U.S. Approval: 2015. 2015."},{"key":"615_CR34","unstructured":"National Department of Health. Master Health Product List of South Africa. South Africa. 2020."},{"key":"615_CR35","unstructured":"National Department of Health. Medicines Price Registry. South Africa.2019."},{"issue":"4","key":"615_CR36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3111\/13696990903336597","volume":"12","author":"M Hammer","year":"2009","unstructured":"Hammer M, Lammert M, Mej\u00edas SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281\u201390.","journal-title":"J Med Econ"},{"key":"615_CR37","unstructured":"Naomi Massyn CD, Noluthando Ndlovu, Thesandree Padayachee. District Health Barometer. Health Systems Trust. 2019\/20."},{"key":"615_CR38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1477-7525-11-90","volume":"11","author":"M Evans","year":"2013","unstructured":"Evans M, Khunti K, Mamdani M, Galbo-J\u00f8rgensen CB, Gundgaard J, B\u00f8gelund M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90.","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"615_CR39","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/0272989X16658660","volume":"36","author":"T Peasgood","year":"2016","unstructured":"Peasgood T, Brennan A, Mansell P, Elliott J, Basarir H, Kruger J. The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes. Med Decis Making. 2016;36(8):1020\u201333.","journal-title":"Med Decis Making"},{"key":"615_CR40","volume":"9","author":"T Zhou","year":"2021","unstructured":"Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health-related quality of life in patients with different diseases measured with the EQ-5D-5L: A systematic review. Front Public Health. 2021;9: 675523.","journal-title":"Front Public Health"},{"key":"615_CR41","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5459","volume":"349","author":"AC Tricco","year":"2014","unstructured":"Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: Systematic review and network meta-analysis. BMJ. 2014;349: g5459.","journal-title":"BMJ"},{"key":"615_CR42","volume-title":"Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non- pregnant adults with diabetes mellitus","author":"World Health Organization (WHO)","year":"2018","unstructured":"World Health Organization (WHO). Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non- pregnant adults with diabetes mellitus. Geneva: WHO; 2018."},{"issue":"5","key":"615_CR43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/dmrr.2500","volume":"30","author":"K Laubner","year":"2014","unstructured":"Laubner K, Molz K, Kerner W, Karges W, Lang W, Dapp A, et al. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German\/Austrian DPV-wiss database. Diabetes Metab Res Rev. 2014;30(5):395\u2013404.","journal-title":"Diabetes Metab Res Rev"},{"issue":"25","key":"615_CR44","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000020553","volume":"99","author":"JC Mbanya","year":"2020","unstructured":"Mbanya JC, Naidoo P, Kolawole BA, Tsymbal E, McMaster A, Karamchand S, et al. Management of adult patients with type 1 diabetes mellitus in Africa: A post-hoc cohort analysis of 12 African countries participating in the International Diabetes Management Practices Study (Wave 7). Medicine (Baltimore). 2020;99(25): e20553.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"615_CR45","doi-asserted-by":"crossref","first-page":"528","DOI":"10.7196\/SAMJ.2017.v107i6.12098","volume":"107","author":"TSA Sehloho","year":"2017","unstructured":"Sehloho TSA, Van Zyl DG. Effects of exogenous human insulin dose adjustment on body mass index in adult patients with type 1 diabetes mellitus at Kalafong Hospital, Pretoria, South Africa, 2009\u20132014. S Afr Med J. 2017;107(6):528\u201334.","journal-title":"S Afr Med J"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00615-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00615-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00615-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T13:35:21Z","timestamp":1742736921000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-025-00615-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00615-x","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"assertion":[{"value":"5 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Secondary data was used throughout the study and ethics approval was granted by the University of Cape Town Human Research Ethics Committee (HREC REF: 670\/2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9"}}